Physician

Sumeet Chandra, M.D.

According to 2025 Medicare claims, Sumeet Chandra, M.D. (NPI: 1801853171) practices hematology/oncology in the Palm Bay-Melbourne-Titusville, FL market, with the plurality of this provider's patient population coming from Brevard, FL. This provider's primary affiliated billing organization is CANCER CARE CENTERS OF BREVARD INC (NPI: 1467551762; TIN: 593169766) and primary practice location at 32935-3145. Chandra is affiliated with the Primary Care Alliance, LLC (ACO ID: D0010), participating under the REACH model.

Chandra's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,013 traditional Medicare patients, billed 349,981 HCPCS/CPT codes, and received $5,814,629 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 672 prescription claims across 172 beneficiaries totaling $2,009,334 in drug costs, led by Revlimid (Lenalidomide). 2022 DME data shows 13 claims. Open Payments data shows 93 records totaling $12,767. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $1,833,097 to $5,814,629. Similarly, Part D prescription costs have risen steadily, from $1,080,043 to $2,009,334. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	739	214,019	$1,833,097
2016	854	257,311	$2,314,898
2017	786	240,016	$2,242,487
2018	884	333,894	$4,025,669
2019	979	495,940	$5,236,010
2020	875	520,430	$5,673,210
2021	895	482,516	$4,963,240
2022	903	503,186	$5,248,320
2023	962	389,058	$5,415,160
2024	1,013	349,981	$5,814,629

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	162	964	$1,080,043
2016	180	885	$1,045,204
2017	142	580	$1,181,850
2018	133	526	$980,658
2019	136	633	$1,709,905
2020	146	648	$1,586,196
2021	149	660	$1,141,934
2022	150	547	$1,273,447
2023	143	568	$2,101,936
2024	172	672	$2,009,334

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	72	$39,681
2016	N/R	51	$13,503
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	13	$1,087
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	359	1,034	$101
99203	New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more	211	211	$85
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	704	1,304	$70
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	156	318	$49
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	580	1,085	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	44	1,148	$673,878
Lenalidomide	Lenalidomide	50	1,337	$622,374
Imbruvica	Ibrutinib	20	583	$247,625
Brukinsa	Zanubrutinib	12	360	$77,022
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	65	1,870	$4,473

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	87	$2,020	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	6	$10,747	Tolmar, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Sumeet Chandra, M.D.?

Tedicare shows public-source Medicare data for Sumeet Chandra, M.D. (NPI 1801853171), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Sumeet Chandra, M.D. have ACO affiliation data?

Sumeet Chandra, M.D. is shown with ACO affiliation data for Primary Care Alliance, LLC (REACH, ACO ID D0010).

What billing organization is linked to Sumeet Chandra, M.D.?

Sumeet Chandra, M.D. is linked to CANCER CARE CENTERS OF BREVARD INC (billing NPI 1467551762) in the available physician profile data.

Does Sumeet Chandra, M.D. have Open Payments data?

Sumeet Chandra, M.D. has 93 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.